Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.38

-9.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (16743)	5/10/2005 10:04:21 AM
From: former_pgs	Read Replies (1) of 52153

I agree with you. 11% of 40 patients is 4.4 patients. 22% of 40 patients is 8.8 patients. The numbers don't make sense, but I suspect that not all of the 40 patients had measurable disease? One thing that is not clear to me from this PR is what criteria they used for objective response. RECIST or CA-125? If I'm right about the above comment regarding measurable disease, I may have answered my own question. But it would be good to know, regardless.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next